---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-091022"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:11:12.750676+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health Q2 net loss $12.2M, revenue $2.7M (+36% QoQ); OnTarget Phase 3 topline due late Oct

## Summary
- Net loss attributable to shareholders $12.2M in Q2 2023 vs $9.4M in Q2 2022; diluted EPS ($0.42) vs ($0.12).
- Combined net revenue for Mytesi and Canalevia-CA1 $2.7M, up 36% QoQ but down 8% YoY.
- Loss from operations increased to $8.1M from $6.5M YoY; R&D spend rose to $4.3M from $2.5M.
- Mytesi prescription volume up 4% sequentially; Canalevia-CA1 net revenue $39K (+40% QoQ).
- Top line results from Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea expected late October 2023.

## SEC filing metadata
- accession: 0001104659-23-091022
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000110465923091022/0001104659-23-091022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000110465923091022/tm2323630d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-091022
- JSON: https://secwatch.observer/filing/0001104659-23-091022.json
- Plain text: https://secwatch.observer/filing/0001104659-23-091022.txt

## Key facts
- Earnings Releases
  Jaguar Health, Inc. reported second quarter 2023 results: revenue approximately $2.7 million.
  - Period: second quarter 2023
  - Revenue: approximately $2.7 million
  - Result: reported results
  source text: was approximately $2.7 million in the second quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000110465923091022/0001104659-23-091022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.